Section of Clinical, Allergological and Venerological Dermatology Department of Clinical Medicin and Surgery University of Naples Federico II, Naples, Italy -
G Ital Dermatol Venereol. 2014 Feb;149(1):123-30.
The aim of the present study was to evaluate the efficacy and safety of narrowband UVB (NB-UVB) compared with tacrolimus ointment 0.1% in patients with bilateral vitiligo.
In this comparative study, four groups of patients were randomized. Each group was composed by 12 patients with bilateral vitiligo; in each group, every patient was irradiated with NB-UVB (length: 311 nm) twice a week for 9 months and applied tacrolimus ointment 0.1% twice a day on the other area in the same period. Before starting therapy and after 3, 6 and 9 months of therapy, a clinical and photographic evaluation of percentage of repigmentation was performed and Dermatology Life Quality Index Questionnaire was fulfilled.
A repigmentation at least partial occurred in 71% of patients after 36 weeks of treatment with tacrolimus ointment 0.1%; in the whole sample, 14 patients (29%) showed no repigmentation at all, with 2 of them discontinuing the therapy because of side effects (erythema and folliculitis-like manifestations). A homogeneous repigmentation at least partial occurred in 69% of patients after 36 weeks of treatment with NB-UVB; in the whole sample 15 patients (31%) showed no repigmentation at all, with 1 of them discontinuing the therapy because of side effects.
The present study confirmed that the efficacy of NB-UVB phototherapy in vitiligo is comparable to tacrolimus ointment 0.1% therapy. On the basis of our study, we may suggest tacrolimus ointment 0.1% as an alternative to NB-UVB therapy for treating vitiligo.
本研究旨在评估窄谱中波紫外线（NB-UVB）与他克莫司软膏 0.1%在双侧白癜风患者中的疗效和安全性。
在这项比较研究中，将四组患者随机分组。每组由 12 例双侧白癜风患者组成；在每组中，每位患者在同一时期每周接受 NB-UVB（波长：311nm）照射两次，同时在另一个区域每天涂抹他克莫司软膏 0.1%两次。在开始治疗前以及治疗 3、6 和 9 个月后，对患者进行临床和照片评估，以评估复色百分比，并填写皮肤病生活质量指数问卷。
在使用他克莫司软膏 0.1%治疗 36 周后，有 71%的患者出现至少部分复色；在整个样本中，有 14 名患者（29%）完全没有复色，其中 2 名患者因不良反应（红斑和类似毛囊炎的表现）而停止治疗。在使用 NB-UVB 治疗 36 周后，有 69%的患者出现至少部分均匀复色；在整个样本中，有 15 名患者（31%）完全没有复色，其中 1 名患者因不良反应而停止治疗。
本研究证实 NB-UVB 光疗在白癜风中的疗效与他克莫司软膏 0.1%治疗相当。基于我们的研究，我们可以建议他克莫司软膏 0.1%作为 NB-UVB 治疗的替代方法，用于治疗白癜风。
